GNCAQ — Genocea Biosciences Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$12.49m
- $1.64m
Annual income statement for Genocea Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 1.36 | 1.64 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 55.3 | 39.5 | 39 | 48.3 | 53.7 |
Operating Profit | -55.3 | -39.5 | -39 | -47 | -52.1 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -56.7 | -27.8 | -39 | -43.7 | -33.2 |
Net Income After Taxes | -56.7 | -27.8 | -39 | -43.7 | -33.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -56.7 | -27.8 | -39 | -43.7 | -33.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -56.7 | -27.8 | -39 | -43.7 | -33.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -15.1 | -2.69 | -1.89 | -0.984 | -0.484 |
Dividends per Share |